Skip to main content

Advertisement

SpringerLink
Log in

Vasculitides and the Complement System: a Comprehensive Review

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Systemic vasculitides are a group of rare diseases characterized by inflammation of the arterial or venous vessel wall, causing stenosis or thrombosis. Clinical symptoms may be limited to skin or to other organs or may include multiple manifestations as systemic conditions. The pathogenesis is related to the presence of leukocytes in the vessels and to the IC deposition, which implies the activation of the complement system (CS) and then the swelling and damage of vessel mural structures. The complement system (CS) is involved in the pathogenesis of several autoimmune diseases, including systemic vasculitides. This enzymatic system is a part of the innate immune system, and its function is linked to the modulation of the adaptive immunity and in bridging innate and adaptive responses. Its activation is also critical for the development of natural antibodies and T cell response and for the regulation of autoreactive B cells. Complement triggering contributes to inflammation-driven tissue injury, which occurs during the ischemia/reperfusion processes, vasculitides, nephritis, arthritis, and many others diseases. In systemic vasculitides, a group of uncommon diseases characterized by blood vessel inflammation, the contribution of CS in the development of inflammatory damage has been demonstrated. Treatment is mainly based on clinical manifestations and severity of organ involvement. Evidences on the efficacy of traditional immunosuppressive therapies have been collected as well as data from clinical trials that involve the modulation of the CS. In particular in small-medium-vessel vasculitides, the CS represents an attractive target. Herein, we reviewed the pathogenetic role of CS in these systemic vasculitides as urticarial vasculitis, ANCA-associated vasculitides, anti-glomerular basement membrane disease, cryoglobulinaemic vasculitides, Henoch-Schönlein purpura/IgA nephropathy, and Kawasaki disease and therefore its potential therapeutic use in this context.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL (2005) Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 53:93–99

    Article  PubMed  Google Scholar 

  2. Waller R, Ahmed A, Patel I, Luqmani R (2013) Update on the classification of vasculitis. Best Pract Res Clin Rheumatol 27:3–17

    Article  PubMed  Google Scholar 

  3. Fauci AS, Haynes BF, Katz P (1978) The spectrum of vasculitis: clinical, pathological, immunologic, and therapeutic considerations. Ann Intern Med 89:660–676

    Article  CAS  PubMed  Google Scholar 

  4. Lie JT (1994) Nomenclature and classification of vasculitis: plus ça change, plus c’est la même chose. Arthritis Rheum 37:181–186

    Article  CAS  PubMed  Google Scholar 

  5. Jennette JC (2013) Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 17:603–606

    Article  PubMed Central  PubMed  Google Scholar 

  6. Brogan PA (2007) What’s new in the aetiopathogenesis of vasculitis? Pediatr Nephrol 22:1083–1094

    Article  PubMed  Google Scholar 

  7. Hoffman GS, Calabrese LH (2014) Vasculitis: determinants of disease patterns. Nat Rev Rheumatol. doi:10.1038/nrrheum.89

    PubMed  Google Scholar 

  8. Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68:310–317

    Article  CAS  PubMed  Google Scholar 

  9. Mizuno M, Morgan BP (2004) The possibilities and pitfalls for anti-complement therapies in inflammatory diseases. Curr Drug Targets Inflamm Allergy 3:87–96

    Article  CAS  PubMed  Google Scholar 

  10. Ballanti E, Perricone C, Greco E, Ballanti MD, Muzio G, Chimenti MS, Perricone R (2013) Complement and autoimmunity. Immunol Res 56:477–491

    Article  CAS  PubMed  Google Scholar 

  11. Lay WH, Nussenzweig V (1968) Receptors for transducing complex of human B elimination of self-reactive B cells up on complement on leukocytes. J Exp Med 128:991–1009

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Carroll MC (2000) The role of complement in B cell activation and tolerance. Adv Immunol 74:61–88

    Article  CAS  PubMed  Google Scholar 

  13. Nathan C (2002) Points of control in inflammation. Nature 420:846–852

    Article  CAS  PubMed  Google Scholar 

  14. Chen M, Daha MR, Kallenberg CG (2010) The complement system in systemic autoimmune disease. J Autoimmun 34:276–286

    Article  Google Scholar 

  15. Grotz W, Baba HA, Becker JU, Baumgärtel MW (2009) Hypocomplementemic urticarial vasculitis syndrome: an interdisciplinary challenge. Dtsch Arztebl Int 106:756–763

    PubMed Central  PubMed  Google Scholar 

  16. Chang S, Carr W (2007) Urticarial vasculitis. Allergy Asthma Proc 28:97–100

    Article  PubMed  Google Scholar 

  17. Venzor J, Lee WL, Huston DP (2002) Urticarial vasculitis. Clin Rev Allergy Immunol 23:201–216

    Article  PubMed  Google Scholar 

  18. Lienesch DW, Sherman KE, Metzger A, Shen GQ (2006) Anti-Clq antibodies in patients with chronic hepatitis C infection. Clin Exp Rheumatol 24:183–185

    CAS  PubMed  Google Scholar 

  19. Jara LJ, Navarro C, Medina G, Vera-Lastra O, Saavedra MA (2009) Hypocomplementemic urticarial vasculitis syndrome. Curr Rheumatol Rep 11:410–415

    Article  PubMed  Google Scholar 

  20. Brouwer E, Tervaert JW, Horst G, van der Huitema MG, Giessen M, Limburg PC, Kallenberg CG (1991) Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener’s granulomatosis and clinically related disorders. Clin Exp Immunol 83:379–386

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Stone JH, Talor M, Stebbing J et al (2000) Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA-associated conditions. Arthritis Care Res 13:424–434

    Article  CAS  PubMed  Google Scholar 

  22. Danila MI, Bridges SL Jr (2008) Update on pathogenic mechanisms of systemic necrotizing vasculitis. Curr Rheumatol Rep 10:430–435

    Article  CAS  PubMed  Google Scholar 

  23. van der Tervaert JW, Woude FJ, Fauci AS et al (1989) Association between active Wegener’s granulomatosis and anticytoplasmic antibodies. Arch Intern Med 149:2461–2465

    Article  CAS  PubMed  Google Scholar 

  24. Franchi L, Eigenbrod T, Nunez G (2009) Cutting edge: TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J Immunol 183:792–796

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Mariathasan S, Weiss DS, Newton K et al (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440:228–232

    Article  CAS  PubMed  Google Scholar 

  26. Langford CA (2003) Vasculitis. J Allergy Clin Immunol 111(2 Suppl):S602–S612

    Article  CAS  PubMed  Google Scholar 

  27. Lamprecht P, Csernok E, Gross WL (2006) Effector memory T cells as driving force of granuloma formation and autoimmunity in Wegener’s granulomatosis. J Intern Med 260:187–191

    Article  CAS  PubMed  Google Scholar 

  28. Wilde B, Thewissen M, van Damoiseaux J, Paassen P, Witzke O, Tervaert JW (2010) T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells? Arthritis ResTher 12:204

    Article  Google Scholar 

  29. Kallenberg CG (2010) Pathophysiology of ANCA-associated small vessel vasculitis. Curr Rheumatol Rep 12:399–405

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R (2009) C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 20:289–298

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC (2007) Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 170:52–64

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. De Groot K, Rasmussen N, Bacon PA et al (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:2461–2469

    Article  PubMed  Google Scholar 

  33. Pagnoux C, Mahr A, Hamidou MA et al (2008) Azathioprine of methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359:2790–2803

    Article  CAS  PubMed  Google Scholar 

  34. Ballanti ED, Muzio G, Novelli L, Perricone C, Perricone R (2012) Churg-Strauss syndrome with neurologic manifestations: successful treatment with intravenous immunoglobulins. Isr Med Assoc J 14:583–585

    PubMed  Google Scholar 

  35. Svetlicky N, Blank M, Zandman-Goddard G (2012) The beneficial effects of intravenous immunoglobulin for antineutrophil cytoplasmic antibody-positive vasculitis. Isr Med Assoc J 14:568–569

    PubMed  Google Scholar 

  36. Polachek A, Caspi D, Elkayam O (2013) Granulomatosis and polyangiitis: the rituximab option. Isr Med Assoc J 15:193–194

    PubMed  Google Scholar 

  37. Casian, A. (2011), Plasma exchange for severe renal vasculitis: long-term follow-up of the MEPEX trial. Clin. Exp. Immunol. 164 (Suppl. 1):52

  38. Kluth DC, Rees AJ (1999) Anti-glomerular basement membrane disease. J Am Soc Nephrol 10:2446–2453

    CAS  PubMed  Google Scholar 

  39. Segelmark M, Hellmark T, Wieslander J (2003) The prognostic significance in Goodpasture’s disease of specificity, titre and affinity of anti-glomerular- basement-membrane antibodies. Nephron Clin Pract 94:59–68

    Article  Google Scholar 

  40. Lerner RA, Glassock RJ, Dixon FJ (1999) The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Am Soc Nephrol 10:1389–1404

    CAS  PubMed  Google Scholar 

  41. Ohlsson S, Herlitz H, Lundberg S, Selga D, Mölne J, Wieslander J, Segelmark M (2014) Circulating anti-glomerular basement membrane antibodies with predominance of subclass IgG4 and false-negative immunoassay test results in anti-glomerular basement membrane disease. Am J Kidney Dis 63:289–293

    Article  PubMed  Google Scholar 

  42. Fischer EG, Lager DJ (2006) Anti-glomerular basement membrane glomerulonephritis: a morphologic study of 80 cases. Am J Clin Pathol 125:445–450

    Article  PubMed  Google Scholar 

  43. Sheerin NS, Springall T, Carroll MC, Hartley B, Sacks SH (1997) Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice. Clin Exp Immunol 110:403–409

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Otten MA, Groeneveld TW, Flierman R et al (2009) Both complement and IgG fc receptors are required for development of attenuated antiglomerular basement membrane nephritis in mice. J Immunol 183:3980–3988

    Article  CAS  PubMed  Google Scholar 

  45. Hu SY, Jia XY, Yang XW, Yu F, Cui Z, Zhao MH (2013) Glomerular C1q deposition and serum anti-C1q antibodies in anti-glomerular basement membrane disease. BMC Immunol 21:14–42

    Google Scholar 

  46. Hisano S, Matsushita M, Fujita T, Takeshita M, Iwasaki H (2007) Activation of the lectin complement pathway in post-streptococcal acute glomerulonephritis. Pathol Int 57:351–357

    Article  CAS  PubMed  Google Scholar 

  47. Roos A, Rastaldi MP, Calvaresi N et al (2006) Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 17:1724–1734

    Article  CAS  PubMed  Google Scholar 

  48. Harboe M, Mollnes TE (2008) The alternative complement pathway revisited. J Cell Mol Med 12:1074–1084

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Ma R, Cui Z, Liao YH, Zhao MH (2013) Complement activation contributes to the injury and outcome of kidney in human anti-glomerular basement membrane disease. J Clin Immunol 33:172–178

    Article  CAS  PubMed  Google Scholar 

  50. Syeda UA, Singer NG, Magrey M (2013) Anti-glomerular basement membrane antibody disease treated with rituximab: a case based review. Semin Arthritis Rheum 42:567–572

    Article  PubMed  Google Scholar 

  51. Peto P, Salama AD (2011) Update on anti-glomerular basement membrane disease. Curr Opin Rheumatol 23:32–37

    Article  PubMed  Google Scholar 

  52. Dammacco F, Battaglia S, Gesualdo L, Racanelli V (2013) Goodpasture’s disease: a report of ten cases and a review of the literature. Autoimmun Rev 12:1101–1108

    Article  CAS  PubMed  Google Scholar 

  53. Brouet JC, Clouvel JP, Danon F, Klein M, Seligmann M (1974) Biologic and clinical significance of cryoglobulins. Am J Med 57:775–788

    Article  CAS  PubMed  Google Scholar 

  54. Sansonno D, Tucci FA, Ghebrehiwet B et al (2009) Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage. J Immunol 183:6013–6020

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  55. Cacoub P, Saadoun D (2008) Hepatitis C virus infection induced vasculitis. Clin Rev Allergy Immunol 35:30–39

    Article  CAS  PubMed  Google Scholar 

  56. Ferri C, Zignego AL, Pileri SA (2002) Cryoglobulins J Clin Pathol 55:4–13

    Article  CAS  PubMed  Google Scholar 

  57. Vitali C, Ferri C, Nasti P, La Civita L, Mazzantini M, Longombardo G, Bombardieri S (1994) Hypercomplementaemia as a marker of the evolution from benign to malignant B-cell proliferation in patients with type II mixed cryoglobulinaemia. Br J Rheumatol 33:791–792

    Article  CAS  PubMed  Google Scholar 

  58. Tarantino A, Anelli A, Costantino AD, Vecchi A, Monti G, Massaro L (1978) Serum complement pattern in essential mixed cryoglobulinaemia. Clin Exp Immunol 32:77–85

    PubMed Central  CAS  PubMed  Google Scholar 

  59. Sansonno DD, Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101:3818–3826

    Article  CAS  PubMed  Google Scholar 

  60. Saadoun DR, Rigon M, Sene D et al (2010) Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia sequential therapy with antiviral agents. Blood 116:326–334

    Article  CAS  PubMed  Google Scholar 

  61. Ozen S, Pistorio A, Iusan SM et al (2010) EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis 69:798–806

    Article  PubMed  Google Scholar 

  62. Davin JC (2011) Henoch-Schonlein purpura nephritis: pathophysiology, treatment, and future strategy. Clin J Am Soc Nephrol 6:679–689

    Article  PubMed  Google Scholar 

  63. Newburger JW, Takahashi M, Gerber MA et al (2004) Diagnosis, treatment, and long-term management of Kawasaki disease. Circulation 110:2747–2771

    Article  PubMed  Google Scholar 

  64. Burns JC, Glodé MP (2004) Kawasaki syndrome. Lancet 364:533–544

    Article  PubMed  Google Scholar 

  65. Hartopo AB, Setianto BY (2013) Coronary artery sequel of Kawasaki disease in adulthood, a concern for internists and cardiologists. Acta Med Indones 45:69–75

    PubMed  Google Scholar 

  66. Belizna CC, Hamidou MA, Levesque H, Guillevin L, Shoenfeld Y (2008) Infection and vasculitis. Rheumatology (Oxford) 48:475–482

    Article  Google Scholar 

  67. Kaneda Y (1983) Complement system in immunological disease of infants and children: the role of the complement system in Kawasaki disease. Japanese Journal of Allergology 32:376–385

    CAS  PubMed  Google Scholar 

  68. Kohsaka T, Abe J, Asahina T, Kobayashi N (1994) Classical pathway complement activation in Kawasaki syndrome. J Allergy Clin Immunol 93:520–525

    Article  CAS  PubMed  Google Scholar 

  69. Biezeveld MH, Geissler J, Weverling GJ, Kuipers IM, Lam J, Ottenkamp J, Kuijpers TW (2006) Polymorphisms in the mannose-binding lectin gene as determinants of age-defined risk of coronary artery lesions in Kawasaki disease. Arthritis Rheum 54:369–376

    Article  CAS  PubMed  Google Scholar 

  70. Nakamura A, Okigaki M, Miura N, Suzuki C, Ohno N, Kametani F, Hamaoka K (2014) Involvement of mannose-binding lectin in the pathogenesis of Kawasaki disease-like murine vasculitis. Clin Immunol 153:64–72

    Article  CAS  PubMed  Google Scholar 

  71. Hinterseher I, Erdman R, Donoso LA et al (2011) Role of complement cascade in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 31:1653–1660

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  72. Daniels LB, Gordon JB, Burns JC (2012) Kawasaki disease: late cardiovascular sequelae. Curr Opin Cardiol 27:572–577

    Article  PubMed  Google Scholar 

  73. Kobayashi T, Saji T, Otani T et al (2012) Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE-study): a randomized, open-label, blinded-endpoints trial. Lancet 379:1613–1620

    Article  CAS  PubMed  Google Scholar 

  74. Cicardi M, Zanichelli A (2010) Replacement therapy with C1 esterase inhibitors for hereditary angioedema. Drugs Today 46:867–874

    Article  CAS  PubMed  Google Scholar 

  75. Duehrkop C, Banz Y, Spirig R et al (2013) C1 esterase inhibitor reduces lower extremity ischemia/reperfusion injury and associated lung damage. Plos ONE 8:e72059

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  76. Zhang Y, Nester CM, Holanda DG et al (2013) Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. J Am Soc Nephrol 24:1820–1829

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  77. Risitano AM (2012) Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders. Immunobiology 217:1080–1087

    Article  CAS  PubMed  Google Scholar 

  78. Riedl M, Orth-Höller D, Würzner R (2014) An update on the thrombotic microangiopathies hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP). Semin Thromb Hemost 40:413–415

    Article  PubMed  Google Scholar 

  79. Vivarelli M, Emma F (2014) Treatment of c3 glomerulopathy with complement blockers. Semin Thromb Hemost 40:472–477

    Article  CAS  PubMed  Google Scholar 

  80. Radhakrishnan S, Lunn A, Kirschfink M et al (2012) Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 366:1165–1166

    Article  CAS  PubMed  Google Scholar 

  81. Rosenblad, T. Rebetz, J. Johansson, M. Békássy, Z. Sartz, L. Karpman, D. (2014), Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatr. Nephrol. Jun 13

  82. Dairaghi, D. Leleti, M. Miao, S. et al. Clinical dose selection of the C5a receptor antagonist CCX168 for the phase 2 ANCA-associated renal vasculitis clinical trial (the CLEAR trial), 49th European Renal Association–European Dialysis and Transplant Association (ERA–EDTA) Congress, 2012, (Paris, France).

  83. Hartung HP, Mouthon L, Ahmed R, Jordan S, Laupland KB, Jolles S (2009) Clinical applications of intravenous immunoglobulins (IVIg)—beyond immunodeficiencies and neurology. Clin Exp Immunol 158(Suppl 1):23–33

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  84. Ballow M (2011) The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 127:315–323

    Article  CAS  PubMed  Google Scholar 

  85. Smith, R.M. Jones, R.B. Jayne, D.R. (2012), Progress in treatment of ANCA-associated vasculitis. Arthritis Res. Ther.14, 210.

  86. Jayne DR, Chapel H, Adu D, Misbah S, O’Donoghue D, Scott D, Lockwood CM (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93:433–439

    Article  CAS  PubMed  Google Scholar 

  87. Martinez V, Cohen P, Pagnoux C et al (2008) French Vasculitis Study Group. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 58:308–317

    Article  CAS  PubMed  Google Scholar 

  88. Morgan BP, Harris CL (2003) Complement therapeutics; history and current progress. Mol Immunol 40:159–170

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumatology Allergology and Clinical Immunology Department of “Medicina dei Sistemi”, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy

    Maria Sole Chimenti, Eleonora Ballanti, Paola Triggianese & Roberto Perricone

Authors
  1. Maria Sole Chimenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eleonora Ballanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paola Triggianese
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roberto Perricone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Sole Chimenti.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chimenti, M.S., Ballanti, E., Triggianese, P. et al. Vasculitides and the Complement System: a Comprehensive Review. Clinic Rev Allerg Immunol 49, 333–346 (2015). https://doi.org/10.1007/s12016-014-8453-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-014-8453-8

Keywords

Search

Navigation